More threads by David Baxter PhD

David Baxter PhD

Late Founder
FDA approves Lyrica for fibromyalgia

Pfizer has announced that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia.

Characterized by chronic widespread pain that can be relentless, fibromyalgia is usually accompanied by poor sleep, stiffness, fatigue, depression and anxiety; sufferers also report experiencing deep tenderness, soreness and flu-like aching. The pain of fibromyalgia can hamper a patient's ability to work and often results in increased medical costs and disability.

Fibromyalgia is thought to result from neurological changes in how patients perceive pain, specifically a heightened sensitivity to stimuli that are not normally painful. Lyrica® binds to a specific protein within overexcited nerve cells and works to calm damaged nerves. This is thought to reduce the level of pain in patients suffering from fibromyalgia, although the exact mechanism of how Lyrica acts in fibromyalgia is not known.

Lyrica® is also approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia, and as an adjunctive therapy for adult patients with partial onset seizures.
Replying is not possible. This forum is only available as an archive.